|
1
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Duong HQ, Hwang JS, Kim HJ, Kang HJ, Seong
YS and Bae I: Aldehyde dehydrogenase 1A1 confers intrinsic and
acquired resistance to gemcitabine in human pancreatic
adenocarcinoma MIA PaCa-2 cells. Int J Oncol. 41:855–861.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344.
2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ishiwata T, Matsuda Y, Yoshimura H, Sasaki
N, Ishiwata S, Ishikawa N, Takubo K, Arai T and Aida J: Pancreatic
cancer stem cells: Features and detection methods. Pathol Oncol
Res. 24:797–805. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kim SK, Kim H, Lee DH, Kim TS, Kim T,
Chung C, Koh GY, Kim H and Lim DS: Reversing the intractable nature
of pancreatic cancer by selectively targeting ALDH-high,
therapy-resistant cancer cells. PLoS One. 8(e78130)2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Moreb JS: Aldehyde dehydrogenase as a
marker for stem cells. Curr Stem Cell Res Ther. 3:237–246.
2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lin L, Jou D, Wang Y, Ma H, Liu T, Fuchs
J, Li PK, Lü J, Li C and Lin J: STAT3 as a potential therapeutic
target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer
cells. Int J Oncol. 49:2265–2274. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huang EH, Hynes MJ, Zhang T, Ginestier C,
Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM: Aldehyde
dehydrogenase 1 is a marker for normal and malignant human colonic
stem cells (SC) and tracks SC overpopulation during colon
tumorigenesis. Cancer Res. 69:3382–3389. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Park JW, Jung KH, Lee JH, Moon SH, Cho YS
and Lee KH: Inhibition of aldehyde dehydrogenase 1 enhances the
cytotoxic effect of retinaldehyde on A549 cancer cells. Oncotarget.
8:99382–99393. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
MacDonagh L, Gallagher MF, Ffrench B,
Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V,
et al: Targeting the cancer stem cell marker, aldehyde
dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.
Oncotarget. 8:72544–72563. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Landen CN Jr, Goodman B, Katre AA, Steg
AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson
DM, et al: Targeting aldehyde dehydrogenase cancer stem cells in
ovarian cancer. Mol Cancer Ther. 9:3186–3199. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fleischman AG: ALDH marks leukemia stem
cell. Blood. 119:3376–3377. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Morgan CA, Parajuli B, Buchman CD, Dria K
and Hurley TD: N,N-diethylaminobenzaldehyde (DEAB) as a substrate
and mechanism-based inhibitor for human ALDH isoenzymes. Chem Biol
Interact. 234:18–28. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Koppaka V, Thompson DC, Chen Y, Ellermann
M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD and
Vasiliou V: Aldehyde dehydrogenase inhibitors: A comprehensive
review of the pharmacology, mechanism of action, substrate
specificity, and clinical application. Pharmacol Rev. 64:520–539.
2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hoang VT, Hoffmann I, Borowski K,
Zepeda-Moreno A, Ran D, Buss EC, Wuchter P, Eckstein V and Ho AD:
Identification and separation of normal hematopoietic stem cells
and leukemia stem cells from patients with acute myeloid leukemia.
Methods Mol Biol. 1035:217–230. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang W, Bochtler T, Wuchter P, Manta L, He
H, Eckstein V, Ho AD and Lutz C: Mesenchymal stromal cells
contribute to quiescence of therapy-resistant leukemic cells in
acute myeloid leukemia. Eur J Haematol. 99:392–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kallifatidis G, Labsch S, Rausch V,
Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV and
Herr I: Sulforaphane increases drug-mediated cytotoxicity toward
cancer stem-like cells of pancreas and prostate. Mol Ther.
19:188–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kim MP, Fleming JB, Wang H, Abbruzzese JL,
Choi W, Kopetz S, McConkey DJ, Evans DB and Gallick GE: ALDH
activity selectively defines an enhanced tumor-initiating cell
population relative to CD133 expression in human pancreatic
adenocarcinoma. PLoS One. 6(e20636)2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mueller MT, Hermann PC, Witthauer J,
Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M,
Bartenstein P, D'Haese JG, et al: Combined targeted treatment to
eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Gastroenterology. 137:1102–1113. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jimeno A, Feldmann G, Suárez-Gauthier A,
Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E,
López-Ríos F, Matsui W, et al: A direct pancreatic cancer xenograft
model as a platform for cancer stem cell therapeutic development.
Mol Cancer Ther. 8:310–314. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kawamoto M, Umebayashi M, Tanaka H, Koya
N, Nakagawa S, Kawabe K, Onishi H, Nakamura M and Morisaki T:
Combined gemcitabine and metronidazole is a promising therapeutic
strategy for cancer stem-like cholangiocarcinoma. Anticancer Res.
38:2739–2748. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sawada O, Perusek L, Kohno H, Howell SJ,
Maeda A, Matsuyama S and Maeda T: All-trans-retinal induces Bax
activation via DNA damage to mediate retinal cell apoptosis. Exp
Eye Res. 123:27–36. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jin Z and El-Deiry WS: Overview of cell
death signaling pathways. Cancer Biol Ther. 4:139–163.
2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326.
1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Meng E, Mitra A, Tripathi K, Finan MA,
Scalici J, McClellan S, Madeira da Silva L, Reed E, Shevde LA,
Palle K and Rocconi RP: ALDH1A1 maintains ovarian cancer stem
cell-like properties by altered regulation of cell cycle checkpoint
and DNA repair network signaling. PLoS One.
9(e107142)2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Canuto RA, Muzio G, Salvo RA, Maggiora M,
Trombetta A, Chantepie J, Fournet G, Reichert U and Quash G: The
effect of a novel irreversible inhibitor of aldehyde dehydrogenases
1 and 3 on tumour cell growth and death. Chem Biol Interact.
130-132:209–218. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Won M, Luo Y, Lee DH, Shin E, Suh DS, Kim
TH, Jin H and Bae J: BAX is an essential key mediator of
AP5M1-induced apoptosis in cervical carcinoma cells. Biochem
Biophys Res Commun. 518:368–373. 2019.PubMed/NCBI View Article : Google Scholar
|
